Ranbaxy Posts Loss After Write-Offs on US Import Bans

Drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by Sun Pharmaceutical Industries Ltd for $3.2 billion (Rs 19201.6 crore at $1 = 60.0050 rupees), posted a loss in the March quarter, hit by write-offs related to regulatory sanctions.

A series of import bans by US regulators on Ranbaxy's plants, citing poor manufacturing quality, has hurt sales in the United States, its primary export market.

The US Food and Drug Administration (FDA) in January banned the sale of drugs made with ingredients prepared at Ranbaxy's Toansa plant in India after an inspection found the factory's processes did not meet the FDA's manufacturing standards.

Ranbaxy, owned by Japan's Daiichi Sankyo Ltd, said on Friday it had made a provision of Rs 62.95 crore ($10.5 million) in the quarter for inventory write-offs and other costs related to the ban.

It also made a provision of about Rs 70 crore for impairment of goodwill in subsidiaries and reduction in the value of an investment in an associate, the company said in a statement. It did not give details.

As a result, Ranbaxy reported a net loss of Rs 73.654 crore for January-March, compared with a profit of Rs 126 crore a year ago. The mean estimate of 22 analysts was for a profit of Rs 95.87 crore, according to Thomson Reuters data.

Net sales rose 1.2 per cent to Rs 2,440 crore.

Ranbaxy said it had responded to the FDA's concerns related to the Toansa plant and that shipments from the facility were likely to be "resumed shortly".

The Toansa ban followed similar action at Ranbaxy's three other India plants. That left its New Jersey subsidiary Ohm Laboratories Inc as its only permitted maker of drugs for a market that accounted for 32 per cent of sales in the latest quarter.

The company is working closely with regulatory agencies to address their concerns, chief executive Arun Sawhney said in a statement.

Shares in Ranbaxy, valued at about $3.3 billion, ended down 1.3 per cent at Rs 463.55 on Friday, while the Mumbai market rose 3 per cent.

Copyright @ Thomson Reuters 2014

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search